Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29947435 | 1.00 | P2RX7 (0.56) | P2RX7MAPK1CTNNB1WNT3AGRM4 | |
| Hydrochloric Acid SCHEMBL28392257 | 0.98 | P2RX7 (0.55) | P2RX7MAPK1CTNNB1WNT3AGRM4 | |
| Formic Acid SCHEMBL15822388 | 0.93 | P2RX7 (0.50) | P2RX7MAPK1CTNNB1WNT3AGRM4 | |
| SCHEMBL28281561 | 0.87 | P2RX7 (0.53) | P2RX7MAPK1CTNNB1WNT3AGRM4 | |
| SCHEMBL29112193 | 0.83 | KDM4E (0.50) | P2RX7MAPK1KDM4EALDH1A1POLB | |
| SCHEMBL30629294 | 0.82 | P2RX7 (0.44) | P2RX7MAPK1CTNNB1WNT3AGRM4 | |
| SCHEMBL11881388 | 0.81 | P2RX7 (0.49) | P2RX7MAPK1CTNNB1WNT3AGRM4 | |
| SCHEMBL1478698 | 0.80 | P2RX7 (0.52) | P2RX7CTNNB1WNT3AGRM4FAAH | |
| SCHEMBL28179627 | 0.80 | P2RX7 (0.56) | P2RX7CTNNB1WNT3AGRM4FAAH | |
| SCHEMBL23293557 | 0.79 | P2RX7 (0.47) | P2RX7MAPK1CTNNB1WNT3AGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109561682-A | Pyridine compounds and their comprising isoxazoline ring and its purposes as herbicide | 牧牛研究所株式会社 | 2019-04-02 | — | — | CN | claimed |
| CN-106810538-A | A kind of preparation method of 2 pyrrole radicals pyrimidine derivatives | 湖南华腾制药有限公司 | 2017-06-09 | — | — | CN | claimed |
| CN-104327084-B | The small molecule myristate inhibitors and its application method of BCR ABL | 达那-法伯癌症研究所 | 2017-06-06 | — | — | CN | claimed |
| CN-103827117-B | Tetrahydrochysene triazolopyrimidine derivative as people's inhibitors of neutrophil elastase | 奇斯药制品公司 | 2016-08-24 | — | — | CN | claimed |
| CN-102858773-B | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as COPD | CHIESI FARMA SPA | 2015-05-06 | — | — | CN | claimed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | claimed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | claimed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | claimed |
| WO-2010146031-A2 | FUNGICIDAL MIXTURES | BASF SE (DE) | 2010-12-23 | — | — | WO | claimed |
| CN-101917849-A | Small molecule myristate inhibitors of BCR-ABL and methods of use thereof | DANA FARBER CANCER INST INC | 2010-12-15 | — | — | CN | claimed |
| CN-101351467-A | 3- (substituted amino) -pyrazolo [3, 4-d ] pyrimidines as EphB and VEGFR2 kinase inhibitors | NOVARTIS AG (CH) | 2009-01-21 | — | — | CN | claimed |
| CN-101305000-A | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-12 | — | — | CN | claimed |
| CN-101300258-A | 5-OXO-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-05 | — | — | CN | claimed |
| CN-1738806-A | Oxo-azabicyclic compounds | WARNER LAMBERT CO (US) | 2006-02-22 | — | — | CN | claimed |
| CN-1349535-A | Bicyclic heteroaromatic compounds useful as LH agonists | AKZO NOBEL NV (NL) | 2002-05-15 | — | — | CN | claimed |
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| CN-119528915-A | Compounds for inhibiting apoptosis and methods of making the same | 中国科学院上海有机化学研究所 | 2025-02-28 | — | — | CN | disclosed |
| US-4138487-A | NEMATOCIDES | RHONE-POULENC INDUSTRIES (FR) | 1979-02-06 | — | — | US | disclosed |
| US-4110450-A | BILHARZIASIS | RHONE-POULENC INDUSTRIES (FR) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | P2RX7 3830/4885MAPK1 97/4885CTNNB1 2533/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | P2RX7 2015/4885MAPK1 684/4885CTNNB1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.